Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


HCV therapy and risk of liver cancer recurrence: who to treat?

Recurrence of hepatocellular carcinoma after resection or ablation with curative intent is common and not prevented by direct-acting antiviral agent (DAA) therapy for hepatitis C. Owing to multiple methodological inconsistencies, available studies fail to answer whether DAA therapy anticipated risk of severe tumour recurrence: a prospective randomized study might serve the purpose.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Backus, L. I. et al. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology (2017).

    Article  PubMed  Google Scholar 

  2. Backus, L. I. et al. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology (2018).

    Article  PubMed  Google Scholar 

  3. Huang, A. C. et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology (2018).

    Article  PubMed Central  PubMed  Google Scholar 

  4. Roche, B. et al. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int. 38 (Suppl. 1), 139–145.

  5. Terrault, N. A. et al. International liver transplantation society consensus statement on hepatitis c management in liver transplant candidates. Transplantation 101, 945–955 (2017).

  6. Reig, M. et al. Liver cancer emergence associated with antiviral treatment: an immune surveillance failure? Semin. Liver Dis. 37, 109–118 (2017).

  7. Reig, M. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 65, 719–726 (2016).

  8. Colombo, M. & Boccaccio, V. Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests. J. Viral. Hepat. (2018).

    Article  PubMed  Google Scholar 

  9. Singal, A. G. et al. Direct acting antiviral therapy is associated with shorter time to HCC recurrence but not increased risk of recurrence [abstract]. Hepatology 66 (Suppl. 1), 729A (2017).

    Google Scholar 

  10. Cabibbo, G. et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J. Hepatol. 67, 65–71 (2017).

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Massimo Colombo.

Ethics declarations

Competing interests

M.C. has served on the advisory committees for AbbVie, Achillion, AlfaWasserman, Bayer, Bristol–Myers Squibb, GenSpera, Gilead Science, GlaxoSmithKline, Janssen, Jennerex, Lundbeck, MSD, Novartis, Roche, Tibotec and Vertex, and received speaking and teaching fees from AbbVie, Bayer, Bristol–Myers Squibb, Gilead, Janssen, MSD, Novartis, Roche, Sanofi, Tibotec and Vertex. V.B. is on advisory boards for AbbVie and Gilead.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colombo, M., Boccaccio, V. HCV therapy and risk of liver cancer recurrence: who to treat?. Nat Rev Gastroenterol Hepatol 15, 392–393 (2018).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing